PORTFOLIO COMPANY SUMMARY
The RD Fund focuses on companies with late preclinical to clinical stage programs. Preclinical projects are generally within 18 to 24 months of clinical testing. The RD Fund has invested globally in multiple companies, including internally conceived startups working on a range of promising technologies and therapeutic targets, including gene therapy, RNA therapies, neuroprotection and optogenetics.
Nayan Therapeutics is a preclinical stage biopharmaceutical company developing mutation-agnostic therapies to treat inherited retinal diseases.
Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies.
SalioGen Therapeutics is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies.
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
- Opus Genetics
- Vedere Bio II
As of December 2021